ethics committee and the Israelites Ministry of Public Health approvalalready received for of Company’s study with its ownership SCI-210 treatment
TEL AVIV, Israel, Jan. 9, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”) is focused on developing therapeutics to treat disorders. is a professional clinical-stage pharmaceutical company. today announced that it has entered into an agreement with Soroka University Medical Center in Beersheva, Israel (“Soroka Medical Center”) to conduct our clinical study on SCI-210 in patients with autism. . Spectrum Disorder (“ASD”).
In 2022, we received approval from the Israeli Ministry of Health and the Ethics Committee of Soroka University Medical Center, Beersheva, Israel, to conduct our clinical trial.
Oz Adler, CEO of SciSparc, said: “The study in ASD strengthens our advanced clinical program, along with the Phase IIb clinical trial of SCI-110 in patients with Tourette syndrome and the Phase IIa clinical trial of SCI-110 in patients with Alzheimer’s disease and agitation. Soroka Medical Center is Israel’s leading medical center and co-founder and partner of the Israel National Center for Autism and Neurodevelopmental Research, which is dedicated to ASD A leading international center for innovation in translational research, diagnostics and interventions for and other neurodevelopmental conditions, Soroka Medical Center is another in an ongoing effort to collaborate with the world’s leading medical institutions. An example.”
This trial will investigate the efficacy and safety of SciSparc’s drug candidate SCI-210, a proprietary combination of cannabidiol (“CBD”) and CannAmide™, compared to CBD monotherapy in the treatment of ASD.
The aim of this study was to evaluate the safety, tolerability, and efficacy of SCI-210 in children with ASD in a randomized, double-blind, placebo-controlled crossover study. The study design included a 20-week, randomized, double-blind, placebo-controlled, crossover clinical trial in 60 children. The trial has three primary efficacy endpoints. Clinician-implemented clinical global impression improvement (CGI-I). and an effective therapeutic dose.
ASD is a developmental brain condition that affects how a person perceives and interacts with others, causing problems with social interaction and communication. The term “spectrum” in autism spectrum disorders refers to a wide range of symptoms and severity.
almost rhinoceros park Co., Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialist clinical-stage pharmaceutical company led by an experienced team of senior management and scientists. SciSparc’s focus is to create and enhance a portfolio of cannabinoid pharmaceutical-based technologies and assets. With this focus, we are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD. SCI-160 for the treatment of pain; SCI-210 for the treatment of ASD and status epilepticus.
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. For example, SciSparc has developed a plan to evaluate the potential benefits of SCI-210 treatment and the safety, tolerability and efficacy of SCI-210 in children with ASD in a randomized, double-blind, placebo-controlled study. Forward-looking statements are used in discussions. crossover research. Past results of scientific studies and clinical and preclinical trials are no guarantee that the conclusions of future studies or trials will suggest the same or similar conclusions. Such statements deal with future events and are based on SciSparc’s current expectations and are subject to various risks and uncertainties, and SciSparc’s actual results, performance or achievements may not be accurate in this press release. It may differ materially from what is stated or implied in the description. The forward-looking statements contained in or implied in this press release are made in SciSparc’s Annual Report on Form 20-F filed with the SEC on April 28, 2022 under the heading “Risk Factors.” are subject to other risks and uncertainties, including those discussed in It was later filed with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc makes forward-looking statements only as of the date they are made, whether as a result of new information, future events, circumstances or otherwise. disclaims any intention or obligation to update or revise any statements relating to